Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study

Figure 3 Comparison of changes in hepatitis B virus DNA level, the ratios of alanine aminotransferase normalization and alanine aminotransferase level between the tenofovir amibufenamide and tenofovir alafenamide groups. A: Hepatitis B virus (HBV) DNA levels at baseline week, 24 wk and 48 wk in the tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF) groups; B: HBV-DNA reduction from 24 wk to 48 wk in the TMF and TAF groups; C: Alanine aminotransferase (ALT) normalization rate of TMF and TAF groups at 24 and 48 wk; D: ALT levels at baseline week, 24 wk and 48 wk in the TMF and TAF groups. TMF: Tenofovir amibufenamide; TAF: Tenofovir alafenamide; ALT: Alanine aminotransferase; HBV: Hepatitis B virus.